16 SUPPLEMENTARY NOTATION

**AD-A162** 

Er	(U)		est Availa	ble Cop	y E	7	
250	CAN P CEM35 FILM TO V OF TWIST		REPORT DOCUM	MENTATION I	PAGE		
	REPORT SECURITY CLASSIFICATIO	)N		16 RESTRICTIVE	MARKINGS	·	
	SECURITY CLASSIFICATION AUTH	ORITY		1	AVAILABILITY O		
	DECLASSIFICATION / DOWNGRADING SCHEDULE NA						
	ERFORMING ORGANIZATION REPORT NUMBER(S)			5 MONITORING	ORGANIZATION F	EPORT NUMBER(S)	
	University of Alabama #2			NA .			
	NAME OF PERFORMING OPGAN.	ZATION	66 OFFICE SYMBOL	7a NAME OF MO	ONITORING ORGA	NIZATION	
	University of Alabam	a	(If applicable) NA	Office of	f Naval Rese	earch	
	ADDRESS (City State, and ZIP Code) Department of Microbiology Box BM University, AL 35486			800 N. Qi	y, State, and ZIP Lincy St. n, VA 22217-		
	NAME OF FUNDING SPONSOR'N ORGANIZATION	G	8b Office SYMBOL (If applicable)			ENTIFICATION NU	MBER
	Office of Naval Rese		ONR	N00014-8		·····	
8c.	ADDRESS (City, State, and ZIP Co. 800 N. Quincy St.	de)		10 SOURCE OF F	PROJECT	TASK	WORK UNIT
	Arlington, VA 22217-	5000		ELEMENT NO.	NO	NO	ACCESSION NO
				61153N	RR04108	NR 666-028	ļ
11	TITLE (Include Security Classifica (U) Nonspecific Resi Bordetella pertussis	stance I	nduced by an Im	munopharmaco	logic Agent	Derived From	n
12	PEPSONAL AUTHOR(S) Winters, Alvin Leo;	LeBlanc,	Paul Arthur; S	loan, Gary L	ee		
134	TYPE OF REPORT	136 TIME C FROM <u>8/</u>	OVERED 84 TO 8/85	14 PATE OF REPC 12/17/85	ORT (Year, Month,	Day) 15 PAGE 13 plus	count s reprint
16	SUPPLEMENTARY NOTATION						

17	COSATI CODES		18 SUBJECT TERMS (Continue on reverse if necessary and identify by block number)	
FIELD	GROUP	SUB-GROUP	Key Words: antiviral agent, Bordetella pertussis, lipopoly- saccharide, endotoxin, endotoxin-associated proteins, Boivin	
08				
			antigen, immunomodulation, two dimensional polyacrylamide	

19 ABSTRACT (Continue on reverse if necessary and identify by block number) Administration of Bordetella pertussis vaccine intraperitoneally induces resistance to mouse adenovirus infection. Subcellular fractions of B. pertussis are capable of inducing resistance also. Boivin antigen, a trichloroacetic acid-soluble extract of whole cells, is capable of inducing resistance in the dose range of 0.2-2.0 ug when adsorbed to alum. Biochemical analysis of Boivin antigen indicated that the lipopolysaccharide and protein components were not complexed, but were co-extracted. The lipopolysaccharide (endotoxin) moiety was responsible for the antiviral activity and the endotoxin-associated proteins potentiated the antiviral effect

DTIC FILE COPY

20 DISTRIBUTION / AVAILABILITY OF ABSTRACT	21. ABSTRACT SECURITY CLASSIFICAT	ION
MUNCLASSIFIED/UNLIMITED ☐ SAME AS RPT ☐ DTIC USERS		A
222 NAME OF RESPONSIBLE INDIVIDUAL	22b TELEPHONE (Include Area Code)	22c OFFICE SYMBOL
Dr. J. A. Majde	202-696-4055	ONR

DD FORM 1473, 84 MAR 20030117056

83 APR edition may be used until exhausted All other editions are obsolete

SECURITY CLASSIFICATION OF THIS PAGE

18. gel electrophoresis, Western Blot

) Th	401 Fc	
LD / Dist.	•	
	1	Constant
	(INS)	GGPY PECTED

1.0 BACKGROUND. Administration of <u>Bordetella pertussis</u> vaccine (BPV) intraperitoneally renders a mouse remistant to a subsequent lethal dose challenge of mouse adenovirus. A similar activity has been reported when type 1 herpes simplex virus was used as the challenging virus. During the first contract year we established that the antiviral activity of BPV was not associated with a given phase of <u>B. pertussis</u>, but was associated with a variety of phase I and phase IV <u>B. pertussis</u> strains (1, see attached reprint). Several subcellular fractions of <u>B. pertussis</u> were shown to have antiviral activity, i.e., a 1.0 M NaCl extract of whole cells (produced by Dr. R. D. Lemmon, Connaught Laboratories, Inc., Swiftwater, PA), a cell surface polysaccharide removed from whole cells by shearing in a Waring blender, and lipopolysaccharide (LPS) extracted by the phenol-water method of Westphal. All of these fractions contained endotoxin as detected by the Limulus amoebocyte assay (2).

2.0 IDENTIFICATION OF A BPV COMPONENT WITH ANTIVIRAL ACTIVITY. Dra. Barnet Sultzer, John Craig, and R. Castagna, Downstate Medical Center, SUNY, Brooklyn, NY, reported a marked adjuvancy activity following treatment of mice with endotoxin-associated proteins (EP) derived from B. pertussis (3). EP is derived from Boivin antigen, a trichloroacetic acid soluble LPS-rich extract of whole cells. We extracted Boivin antigen from B. pertussis cells and observed antiviral activity. The EP were co-extracted with LPS, but not complexed with LPS. LPS alone induced antiviral activity, but the presence of EP potentiated the activity tenfold or more. Hereafter, Boivin antigen will be designated as EP-LPS to indicate that the antigen contains both lipopolypolyseccharide and endotoxin-associated proteins.

EP-LPS was extracted in the following manner. B. pertussais cells, strain 10536, were obtained from Dr. Lance Gordon, Connaught Research Institute, Ontario, Canada. Trichloroacetic acid was added to obtain a final concentration of 2.5 % and incubated at 4°C for 3 h. Cell debris was removed by centrifugation at 4,000 x g for 30 min. The supernatant was decented and the cells were extracted twice with 2.5 % trichloroacetic acid. The supernatants, bright yellow in color, were pooled and filtered through Whatman No. 40 filter paper to remove floating debris, and dialyzed (molecular weight cut.off 12,000-14,000) against chilled tap water overnight. The dialyzed supernatants were concentrated approximately tenfold by flash evaporation. A slight precipitate developed and was removed by centrifugation at 4,000 x g. EP-LPS was precipitated by addition of ethanol (68% final concentration) and incubation overnight at -18°C. The precipitate was sedimented by centrifugation at 4,000 x g for 30 min and washed with 95% ethanol. The sediment was resuspended in endotoxin-free water and dialyzed against distilled water overnight. The solution was frozen and lyophilized. The resulting light brown crystalline powder (EP-LPS) was stored at -18°C.

The EP-LPS entigen contained 1-10 mg endotoxin per mg (dry weight) as measured by the Limulus amoebocyte assay and 680 ug of protein per mg (dry weight) as measured by the Lowry method. Polyacrylamide gel electrophoresis in the presence of SDS (SDS-PAGE) followed by fixation and staining with PAGE blue 83 revealed seven major polypeptides (62K, 57K, 44K, 39K, 34K, 23.5K, and 18K) and 2 minor polypeptides (90K and 32K). Silver staining of gels by the method of Hitchcock and Brown (4) revealed two species of LPS similar to other B. pertussis strains (5).

Treatment of C3H/HeN mice with <u>B. pertussis</u>-derived EP-LPS entigen rendered the mice resistant to mouse adenovirus infection (Table 1). A dose of 20 ug induced resistance, whereas, a dose of 2.0 ug was not effective (Table 1).

Table 1. Antiviral Activity Associated with EP-LPS Extracted from Bordetella pertussis

Trestment*	Mortality (Deaths/Total)	
EP-LPS, 20 ug	3/10	
EP-LPS, 2.0 ug	10/10	
Water (endotoxim-free)	9/10 .	

<sup>\*</sup> EP-LPS was suspended (1.0 mg/ml) in endotoxin-free water and diluted tenfold in endotoxin-free water. Each preparation (0.5 ml) was injected intraparitoneally seven days prior to intraparitoneal inoculation of mouse adenovirus. Experiments were terminated 21 days after infection.

Previous observations obtained with a subcellular fraction of B. pertussis prepared by Dr. Robert Lemmon, Connaught Laboratories, (1.0 M NaCl extraction, ammonium sulfate precipitation, and Emulphogene treatment) indicated that lower doses of a subcellular fraction (12 ug) could effect resistance against a virus challenge (2). Emulphogene treatment to reduce the LPS content resulted in a hydrophobic, insoluble precipitate; therefore, Dr. Lemmon's subcellular fraction was adsorbed to alum for administration to test animals. The slow release of Dr. Lemmon's fraction from the alum might have increased the potency of the fraction. We adsorbed EP-LPS entigen to the same alum preparation (Alhydrogel) and administered the complex i.p. seven days before challenge with a lethal dose of virus. An increase in potency of EP-LPS entigen was observed (Table 2). As little as 0.02 ug of the alum-adsorbed preparation induced resistance in a portion of the test population.

Table 2. Antiviral Activity Associated with EP-LPS Extracted from Bordetella pertussis and Adsorbed to Alum

Treatment*	Mortality (Deaths/Total)
Experiment 1:	
EP-LPS (20 ug) + Alum	0/10
EP-LPS (2.0 ug) + Alum	1/10
Alum (control)	9/9
Experiment 2:	
EP-LPS (2.0 ug) + Alum	1/10
EP-LPS (0.2 ug) + Alum	4/10
EP-LPS (0.02 ug) + Alum	6/10
Alum (control)	8/10

\*EP-LPS was suspended (1.0 mg/ml) in Alhydrogel, E.M. Sergeant Pulp and Chemical Co., Inc., Hoboken, N.J., and diluted to the appropriate concentration in endotoxin-free water. Each preparation (0.5 ml) was injected intraperitoneally 7 days prior to intraperitoneal insculation of the mouse adenovirus. Experiments were terminated 21 days after infection.

Dr. Bernet Sultzer separated EP-LPS into EP and LF5 using phenol-water precipitation of the proteins. Antiviral activity was retained in the LPS fraction, but not in the EP fraction (Table 3). Twenty micrograms of EP adsorbed to alum induced resistance in only a small portion of the test population; whereas 20 ug of LPS induced resistance in most of the test population. A second experiment with 20 ug of LPS did not demonstrate a great degree of protection; thus a 20 ug dose of LPS may be near the dilution endpoint. Additional testing near the 20 ug dose of LPS is planned to confirm the dilution endpoint of LPS.

Table 3. Antivirel Activity Associated with Endotoxin-associated Proteins (EP) or Lipopolysaccharide (LPS) Derived from <u>Bordetella</u> pertussis EP-LPS and Adsorbed to Alum

Treetment	Mortality (Deaths/Total)
Experiment 1:	
EP (20 ug) + Alum	9/10
LPS (20 ug) + Alum	1/10
Alum	8/10
Experiment 2:	
LPS (20 ug) + Alum	9/10
LPS (2.0 ug) + Alum	11/11
LPS (0.2 ug) + Alua	10/10
Alum	10/10

\*EP or LPS was suspended (1.0 mg/ml) in Alhydrogel, E.M. Sergeant Pulp and Chemical Co., Inc., Hoboken, N.J., and diluted to the appropriate concentration in andotoxin-free water. Each preparation (0.5 ml) was injected intraperitoneally 7 days prior to intraperitoneal inoculation of the mouse adenovirus. Experiments were terminated 21 days after infection.

Adjuvancy activity alone did not account for the antiviral activity. Dr. Barnet Sultzer observed that the EP extracted from EP-LPS possessed immunomodulatory activities essociated with adjuvancy, i.e., both polyclonal activation and mitogenicity. In addition, we have examined a gliding bacteria adjuvant (GBA) for antiviral activity. GBA, provided by Dr. William R. Usinger, University of California, Berkley, CA, has notable adjuvancy activity both in vitro and in vivo (6). The complex polysaccharide is active in picomolar concentrations, atimulates the production of macrophage-derived hormones, IL-2 colony stimulating factor, and tumor necrotizing factor, and stimulates B cell proliferation and immunoglobulin secretion; however, the polysaccharide failed to induce resistance to mouse adenovirus under our test conditions (Table 4). We plan to test higher concentrations of GBA (20-200 ug) for antiviral activity.

Table 4. Lack of Antiviral Activity Associated with Gliding Bacteria Adjuvant Derived from <a href="Cytophaga">Cytophaga</a>

<pre>Hortality (Deaths/Total)</pre>
10/10
9/9
10/10
9/10


\* GBA was suspended (1.0 mg/ml) in Alhydrogel, E.M. Sergeant Pulp and Chemical Co., Inc., Hoboken, N.J., and diluted to the appropriate concentration in endotoxinfree water. Each preparation (0.5 ml) was injected intraperitoneally 7 days prior to intraperitoneal inoculation of the mouse adenovirus. Experiments were terminated 21 days after infection.

It appears that the EP in EP-LPS potentiates the antiviral activity of LPS approximately 10- to 100-fold. We are currently examining the activity of both EP and GBA in reconstruction experiments to determine whether the interaction of these adjuvants with <u>B pertussis</u>-derived LPS will potentiate the antiviral activity.

We have examined EP-LPS to determine whether a unique complex of LPS and protein existed. EP-LPS was electrophoresed in a two-uimensional gal. The first dimension consisted of nondenaturing conditions in a cylindrical 5% acrylamide gel and discontiuous buffers (stacking gel, pH 6.8; resolving gel pH 8.8) to separate the proteins of EP-LPS by charge and not by size (7). After a short equilibration of the first dimension cylindrical gol in SDS-buffer (pH 6.8) the proteins were then electrophoresed in a second dimension consisting of denaturing conditions in a slab 10% acrylamide gel and SDS-buffer (pH 8.8) to separate the proteins by molecular size (8). If EP-LPS existed as a complex then the proteins would be detected in a vertical line parallel with the direction of electrophoresis in the second dimension. PAGE Blue 83 staining of the two dimensional gel revealed the proteins of EP-LPS in the righthand side of the gel and most of the proteins were not oriented in a streight line perallel to the direction of electrophoresis in a denaturing SDS gel (Figure 1). Under the conditions use for electrophoresis the proteins of EP-LPS do not appear to be extracted as a complex.

Figure 1. Two Dimensional Gel Electrophoresis of EP-LPS followed by Protein Stain

First Dimension (nondenaturing 5% gel)




Second Dimension

Silver ataining of LPS followed by PAGE Blue 83 staining revealed the LPS of EP-LPS in the lower lefthand corner of a two dimensional gel and the LPS was well-separated from the proteins (Figure 2).

Two Dimensional Gal Electrophoresis of EP-LPS followed by Silver Staining and Protein Staining


First Dimension (nondensturing 5% gel)



EP-LPS was separated by two dimensional electrophoresis and transferred to nitrocellulose paper by electrophoretic transfer at a pH of 8.3 (9). The nitrocellulose paper was blocked with 10% nonfat dry milk. The blocked paper was then incubated with rabbit antiserum raised against BPV (Connaught Laboratories, Inc.), washed, and incubated with goat enti-rabbit IgG conjugated with horse radish peroxidase. The immunoblot was developed with 4-chloro-1-naphthol and hydrogen peroxide (10). LPS was the immunodominant entigen in EP-LPS. As observed with the silver stain, the two species of B. pertussis LPS was observed in the lower lefthend corner of the two dimensional gel and well separated from the proteins (Figure 3). A single immunodominant protein may have been complexed with LPS during the extraction. This protein migrate poorly in the first dimension and was marginally visible on the PAGE Blue 83 stained two dimensional gels. Taken together, these data indicate that EP-LPS is probably not extracted as a complex, but the components are co-extracted in the 2.5% trichloroacetic acid. Additional two dimensional gels will be silver stained for protein to ascertain the number and characteristics of minor proteins in the EP-LPS extract. We also will examine the purified LPS by Western blot analysis to determine whether the single immuncdominant protein observed in EP-LPS was removed by phenol-water precipitation.

Figure 3. Two Dimensional Gel Electrophoresis of EP-LPS followed by Electrophoretic Transfer To Nitrocellulose Paper and Staining with Enzyme-linked Antibody to BPV (Western Blot).

First Dimension (nondensturing 5% del)



LPS, derived from strains 3779 BL<sub>2</sub>S<sub>4</sub> (2) and 10536 and purified by two different methods, elicits antiviral activity in C3H/HeN mice. These observations support a hypothesis that LPS plays an important, if not a singular role, in the antiviral activity associated with B. pertussis. Using purified LPS we can now begin to examine in detail the immunomodulatory mechanisms that develop following administration of LPS and hopefully associate given mechanisms with the virus resistant state. In addition we can begin to assess the role of adjuvents in this phenomenon.

#### 4.0 REFERENCES

- 1. Winters AL, Beggett DW, Benjamin WR, Brown HK, Klein TW: Resistance to adenovirus infection after administration of Bordetella pertussis vaccine in mice. Infect Immun 47:387-591, 1985.
- 2. Winters Al., Beggett DW, Lee JD, Sloan GL, Lemmon RD, Stinson RS: Immunomodulation by <u>Bordetella pertussis</u>: Antiviral effects. (in press). <u>In CR Manclark and W Hennessen (eds)</u>. Proceedings of the Fourth International Symposium on Pertussis. S. Karger, NY, 1985.
- 3. Sultzer BM, Craig JP, Castagna R: The adjuvent effect of pertussis endotoxin protein in modulating the immune response to cholera toxoid in mice. (in press). In CR Menclark and W Hennessen (eds). Proceedings of the Fourth International Symposium on Pertussis. S. Karger, NY, 1985.
- 4. Hitchcock PJ, Brown TM: Morphological heterogeneity among Salmonelle lipopolysaccheride chemotypes in silver-steined polyacrylamide gels. J Becteriol 154:269-277, 1983.
- 5. Peppler MS: Two physically and serologically distinct lipopolysecheride profiles in strains of <u>Bordetella pertussis</u> and their phenotype variants. Inf Immun 43:224-232, 1984.
- 6. Usinger WR, Nishell RI: Nurine macrophages specifically recognize a polyseccheride polymer from <u>Cytophage</u> that is an immunological adjuvant. Fed Proc 44: 598 (Abst 1097), 1985.
- Reisfeld RA, Lewis UJ, Williams DE: Disk electrophoresis of basic proteins and peptides on polyacrylamide gels. Nature 195:281-283, 1962.
- 8. Leemmii UX: Cleavege of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685, 1970.
- 9. Burnette WN: "Western blotting": electrophoretic trerafer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem 112:195-203, 1981.

8

- 10. Hawkes R, Niday E, Gordon J: A dot-immunobinding assay for monoclonal and other antibodies. Anal Biochem 119: 142-147, 1982.
- 5.0 PUBLICATIONS/PRESENTATIONS RELATED TO THIS PROJECT.

Winters AL, Baggett DW, Benjamin WR, Brown HK, Klein TW: Resistance to adenovirus infection after administration of <u>Bordetella</u> pertussis vaccine in mice. Infect Immun 47:587-591, 1985.

Winters AL, Baggett DW, Lee JD, Sloan GL, Lemmon RD, Stinson RS: Immunomodulation by <u>Bordetella pertussis</u>: Antiviral effects. (in presa). <u>In CR Manulark and W Hennessen (eds)</u>. Proceedings of the Fourth International Symposium on Pertussis. S. Karger, NY, 1985.

Stinson RS, Lemmon RD, Baggett DW, Huff TL, Malone JA, Sloan GL, Winters AL: Removal of lipopolysaccharide from acellular <u>Bordetella</u> <u>pertussis</u> vaccine by detergent treatment. J Biol Standard (submitted and returned for revision).

Winter AL, Baggett DW, Lee JD, Sloan GL, Lexmon RD, Stinson RS: Immunomodulation by <u>Bordetella pertussis</u>: Antiviral effects. Fourth International Symposium on Pertussis, Geneva, Switzerland, September 25-27, 1984.

Baggett DW, LeBlanc PA, Winters AL: Antiviral activity of <u>Bordetella</u> <u>pertussis</u>: Vesicular stometitis virus. Charter Conference of the Inter-American Society for Chemotherapy, Inc., St. Petersburg, FL, December 9-12, 1984.

# Resistance to Adenovirus Infection After Administration of Bordetella pertussis Vaccine in Mice

ALVIN L. WINTERS, 1\* DAVID W. BAGGETT, 1 WILLIAM R. BENJAMIN, 2+ H. KEITH BROWN, 3 AND THOMAS W. KLEIN2

Department of Microbiology, <sup>1</sup>Jniversity of Alubama, University, Aiabama 35486, <sup>1</sup> and Departments of Medical Microbiology and Immunology<sup>2</sup> and Anatomy, <sup>3</sup> University of South Florida, Tampa, Florida 33612

Received 27 August 1984/Accepted 13 November 1984

Treatment of mice with Bordetella pertussis vaccine rendered mice resistant to mouse adenovirus infection. The resistant state took at least 5 days to develop, and susceptibility returned to a portion of the test population 35 days after treatment. Transient resistance developed in congenitally athymic mice also. Treatment with a dose of 25 µg (dry weight) of B. pertussis vaccine protected approximately 50% of the test population. Vaccines prepared from several different strains of B. pertussis were capable of inducing resistance, and the induction of resistance was not dependent on the mouse strain used for testing. Cross-reacting antibodies capable of neutralizing the virus or protecting against a challenging infection were not induced by treatment with B. pertussis vaccine.

A variety of immunomodulatory activities have been associated with Bordetella pertussis vaccine (BPV) (14, 17, 19, 20). Acellular components extracted from the B. pertussis cell can mimic some of these immunomodulatory activities (3, 4, 7, 8, 18, 22, 23). Treatment of mice with BPV or components extracted from B. pertussis can modify the pathogenesis of virus infections. Increased susceptibility to intranasal influenza virus challenge was observed 5 to 7 days after intraperitoneal (i.p.) injection of BPV (21). Increased resistance to intracranial rabies virus challenge was observed when an extract of B. pertussis was administered by the subcutaneous, intravenous, or i.p. route at the same time as the virus (19). Increased resistance to i.p. herpes simplex virus challenge was observed 7 days after i.p. injection of BFV; however, resistance was not observed when BPV was administered 3 days before virus challenge (13). Several acellular fractions of B. pertussis, namely, lipopolysaccharide, glycolipid, lipid A, or lipid X, induce a state of resistance to an i.p. challenge of encephalomyocarditis virus or a subcutaneous challenge of Semliki Forest virus when the B. pertussis-derived fractions were administered i.p. 24 h previously (1, 3). Discussions with the late Charles W. Fishel concerning the immunomodulatory activities of B. pertussis and the reports of antiviral activity of BPV suggested that BPV might modulate mouse adenovirus infection by a plaque-type variant of mouse adenovirus strain FL. The plaque-type varient strain, designated MAd1p14, induces an interstitial pneumonia and death (25). Increased resistance to an i.p. challenge of mouse adenovirus was observed when BPV was injected i.p. 7 days before virus challenge (14). This report extends the characterization of BPV-induced resistance to mouse adenovirus infection.

### **MATERIALS AND METHODS**

Animals. Female mice, strain BDF<sub>1</sub>/Cox (C57Bl/6 Cox  $\times$  DBA/2 Cox) were obtained from Laboratory Supply Co., Indianapolis, Ind. A colony of C3H/HeN (mammary tumor virus positive [MTV<sup>+</sup>]) mice with the nude gene mutation

was obtained from Carl Hansen, National Institutes of Health, Bethesda, Md., and bred and maintained at the University of South Florida, Tampa, Fla., as described previously (24). Male mice heterozygous for the nude gene and female mice homozygous for the nude gene were used in this study. A colony of C3H/HeN (MTV<sup>-</sup>) mice was obtained from Carl Hansen and bred and maintained at the University of Alabama, University. Both male and female mice were used in this study.

Vaccines. BPV was provided by Connaught Laboratories, Swiftwater, Pa., and was adjusted to approximately 4.0 mg (dry weight) per ml in saline-thimerosal diluent (0.15 M NaCl in 0.02% thimerosal). Vaccines were made also from B. pertussis strains 18323 (James L. Cowell, Food and Drug Administration, Bethesda, Md.) and Tohama I (Stanley Falkow, Stanford University, Stanford, Calif.). The organisms were maintained on BG agar base (Difco Laboratories, Detroit, Mich.) supplemented with 17% defibrinated sheep blood. Vaccines were made by harvesting 4-day growth from Cohen-Wheeler agar in phosphate-buffered saline (pH 7.2) and inactivating the cells by heating (56°C for 30 min) in the presence of 0.02% thimerosal. The vaccines were adjusted to 4.0 mg (dry weight) in saline-thimerosal diluent and stored at 4°C.

Virus. MAd1p14 was propagated in L cells (NCTC clone 929; American Type Culture Collection, Rockville, Md.) The virus titer of infecting stocks was determined by a plaque assay (24).

Leukocytosis. Mice were bled from the retroorbital plexus with heparinized capillary tubes. Samples (10 µl) of peripheral blood from each mouse were placed into tubes containing 490 µl of Turk solution (9), mixed, and counted with a hemocytometer.

Electron microscopy. Cells obtained by peritoneal lavage were sedimented by centrifugation at  $450 \times g$  for 10 min. The cell pellet was covered with fixative (2% paraformal-dehyde-3% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.3) and postfixed with osmium tetroxide. After the cell pellet was embedded in epon, ultrathin sections (60 to 70 nm) were stained as previously described (24).

<sup>\*</sup> Corresponding author.

<sup>†</sup> Present address: Hoffmann-LaRoche, Inc., Nutley, N. 07110.

TABLE 1. Induction of resistance to MAd1p14 challenge by BPV administration

and the state of t				
Mouse strain	Treatment	Virus dose (PFU)	Mortality (deaths/ total)	
C3H/HeN (+/nu) (MTV <sup>+</sup> )	Diluent	1.0 × 10 <sup>8</sup>	25/25	
C3H/HeN (+/nu) (MTV <sup>+</sup> )	BPV (Connaught)	$1.0 \times 10^8$	0/20	
BDF <sub>1</sub>	Diluent	$1.0 \times 10^8$	20/20	
BDF <sub>1</sub>	BPV (Connaught)	$1.0 \times 10^{8}$	0/20	
C3H/HeN (MTV <sup>-</sup> )	Diluent	$2.2 \times 10^{7}$	21/2i	
C3H/HeN (MTV-)	BPV (Connaught)	$2.2 \times 10^{7}$	0/21	
C3H/HeN (MTV-)	Diluent	$2.8 \times 10^{7}$	10/10	
C3H/HeN (MTV-)	BPV (13323)	$^{\circ} 8 \times 10^{7}$	0/10	
C3H/HeN (MTV-)	Diluent	$2.6 \times 10^{7}$	5/5	
C3H/HeN (MTV-)	BPV (Tohama I)	2.8 × 10	0/5	

 $<sup>^{\</sup>circ}$  Animals were injected i.p. with either saline-thimerosal diluent or 250 µg (dry weight; of BPV 7 days before i.p. virus challenge.

#### RESULTS

Induction of resistance. Treatment of mice with BPV induced resistance to an MAd1p14 challenge (Table 1). Animals were injected i.p. with BPV; 7 days later, lethal doses of MAd1pt4 were administered. The animals were observed thereafter for clinical disease and death accompanied by hemorrhagic lungs at necropsy. Treatment of mice with BPV induced a resistant state to as much as 20 50% lethal doses of the virus. The treatment protected the mice also from overt clinical signs of disease, such as hunched back, ruffled fur, marked inactivity, and huddling. The long-term survival of mice after BPV treament and MAd1p14 infection was at least 65 days. The longest duration of disease and death observed after MAd1pt4 infection was 11 days; therefore, experiments were scored 21 days after infection. The 50% effective dese of BPV was approximately 25 µg (dry weight) or approximately 1.2 mg/kg of body weight (Table 2).

The kinetics of the induction of the resistant state suggest that BPV was not interacting directly with the virus. The resistant state did not develop immediately after administration of the vaccine, but was observed initially 5 days after BPV treatment (Table 3). The resistant state was transient, and susceptibility returned to a portion of the test population 35 days after BPV treatment.

A functioning thymus was not necessary for induction of the resistant state. Congenitally athymic mice were very susceptible to MAd1pt4 infection (Table 4). The kinetics of disease and death after high-dose virus infection was similar

TABLE 2. Dose response of BPV-induced resistance to MAd1pt4 in BDF<sub>1</sub> mice

Treatment*	Mortality (deaths/ total)
Diluent	. 10/10
2.5 µg of BPV	. 10/10
12.5 μg of BPV	
25 μg of BPV	
125 μg of BPV	. 1/10
250 µg of BPV	. 0/10

<sup>&</sup>lt;sup>a</sup> Mice were injected i.p. with the designated amounts (dry weight) of BPV (Connaught Laboratories) 7 days before i.p. virus challenge with  $1.0 \times 10^8$  PFU.

TABLE 3. Kinetics of BPV-induced resistance to MAd1pt4

Expt	Mouse strain	Time of treatment* (days)	Virus dose (PFU)	Mortality (deaths/ total)
1	BDF,	0.02	1.0 × 10 <sup>8</sup>	5/5
	BDF <sub>1</sub>	7	$1.0 \times 10^{8}$	0/10
	BDF <sub>1</sub>	14	$1.0 \times 10^{8}$	C/10
	BDF,	21	$1.0 \times 10^{8}$	0/10
	BDF <sub>1</sub>	35	$1.0 \times 10^8$	4/10
2	C3H/HeN (MTV <sup>-</sup> )	1	$2.1 \times 10^{7}$	5/5
	C3H/HeN (MTV-)	2	$2.1 \times 10^{7}$	5/5
	C3H/HeN (MTV~)	3	$2.1 \times 10^{7}$	5/5
	C3H/HeN (MTV-)	4	$2.1 \times 10^{7}$	5/5
	C3H/HeN (MTV-)	5	$2.1 \times 10^{7}$	0/5
	C3H/HeN (MTV-)	6	$2.1 \times 10^{7}$	0/5
	C3H/HeN (MTV-)	7	$2.1 \times 10^{7}$	0/5

<sup>&</sup>lt;sup>4</sup> Mice were injected i.p. with 250 μg (dry weight) of BPV (Connaught Laboratories) and challenged with virus at the designated times of treatment. Both experiment• included diluent injected groups of mice as controls; the control groups exhibited 100% mortality.

in both thymus-bearing and athymic animals. Infection with low doses of the virus produced no overt disease or death in thymus-bearing animals, whereas low-dose infection of athymic animals produced a chronic wasting disease and death with hemorrhagic lungs after an extended period of time. A transient BPV-induced resistant state was observed also in congenitally athymic mice. In contrast to the thymus-bearing animals, the athymic animals succumbed to high-dose infection and disease after the resistant state decayed (Table 4).

TABLE 4. Dose response of MAd1pt4 in normal, athymic, and BPV-treated athymic mice

Bry-treated athymic mice				
Mouse strain	Virus challenge (PFU)	Mortality (deaths/ total)	Time of death (days)	
BDF <sub>1</sub>	$1.0 \times 10^8$	10/10	3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3	
BDF <sub>1</sub>	$1.0 \times 10^7$	10/10	3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 4, 4	
BDF <sub>1</sub>	$1.0 \times 10^{6}$	2/10	3, 3	
C3H/HeN (+/nu)	$1.0 \times 10^8$	15/15	3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 5, 5, 5	
C3H/He <sup>+</sup> (+/nu)	$1.0 \times 10^7$	8/10	6, 8, 8, 8, 8, 10, 10, 10	
C3H/HeN (+/nu)	$1.0 \times 10^{6}$	1/10	9	
C3H/HeN (nu/nu)	$1.0 \times 10^{8}$	5/5	5, 5, 5, 5, 6	
C3H/HeN (nu/nu)	$1.0 \times 10^{7}$	5/5	8, 10, 16, 21, 33	
C3H/HeN (nu/nu)	$1.0 \times 10^{6}$	5/5	18, 18, 22, 26, 31	
C3H/HeN (nu/nu)	$1.0 \times 10^{5}$	4/54	35, 38, 38, 38	
C3H/HeN (nu/nu)	$1.0 \times 10^{4}$	5/5	26, 30, 33, 35, 39	
C3H/HeN (nu/nu)	$1.0 \times 10^{3}$	5/5	25, 29, 33, 35, 36	
C3H/HeN (nu/nu)	$1.0 \times 10^{2}$	5/5	33, 33, 36, 36, 45	
BPV-treated	$1.0 \times 10^8$	15/15	7, 11, 37, 38, 39,	
C3H/HeN (nu/nu) <sup>b</sup>		20.00	40, 43, 43, 46, 46, 48, 51, 54, 54, 63	
Diluent-treated C3H/HeN (nu/nu)*	1.0 × 10 <sup>8</sup>	15/15	4, 4, 4, 4, 5, 5, 5, 5, 5, 5, 5, 5, 5, 6, 9	

The survivor was sacrificed by cervical dislocation 149 days after infecion.

Mice were injected with vaccine diluent or 250 µg (dry weight) of BPV (Connaught Laboratories) 7 days before virus challenge.

TABLE 5. Effect of heat treatment on the antiviral activity of

Mouse strain	Treatment	Mortality (deaths/ total)	
C3H/HeN (+/nu)	Diluent	15/15	
C3H/HeN (+/nu)	BPV	0/10	
C3H/HeN (+/nu)	Heated BPV*	0/15	
BDF,	Diluent	5/5	
BDF,	BPV	0/10	
BDF <sub>1</sub>	Heated BPV*	5/10	

<sup>&</sup>lt;sup>6</sup> Mice were injected i.p. with vaccine diluent or 250 µg (dry weight) of BPV (Conneught Laboratories) 7 days before virus challenge.

BPV (Conneught Laboratories) was incubated at 80°C for 30 min before i.p. injection.

Treatment of BPV to inactivate pertussigen (80°C for 30 min) (19) did not affect resistance-inducing activity when assayed in C3H/HeN (+/nu) mice, but decreased activity when assayed in BDF<sub>1</sub> mice (Table 5). The heated vaccine failed to induce lymphocytosis in the peripheral blood of mice (Table 6).

Effects of treatment with BPV. High-dose MAdlp14 infection did not effect a notable generalized immune response (splenomegaly) within 3 days of virus inoculation (Table 7). Treatment of mice with BPV induced a threefold increase in spleen size, and the splenomegaly was retained during 3 days of high-dose virus infection.

High-dose MAdlpt4 infection did not indua an observable increase in the number of peritoneal leukocytes 3 days after infection (Table 8). Similar to a previous study of Fishel and coworkers (5), BPV treatment effected a fivefold increase in peritoneal leukocyte number. The combination of B2V treatment and high-dose virus infection had a synergistic effect, and the peritoneal leukocyte number was increased approximately 10-fold. The activity of the BPV-induced peritoneal lavage cells increased markedly. Electron microscopy of diluent-treated peritoneal exudate cells 3 days after high-dose virus infection revealed numerous virus particles in the extracellular medium and in phagolysosomes (Fig. 1A). In contrast, BPV-treated peritoneal exudate 3 days after high-dose virus infection exhibited virtually no cells with virus particles (Fig. 1B).

Antibodies did not play a role in the development of the BPV-induced resistant state. Treatment of mice with BPV for 10 days did not induce MAd1pt4 neutralizing antibodies. Studies with monoclonal antibodies indicate that certain classes of antibodies do not neutralize, but will protect the test animal against a challenging virus infection (2, 15, 16). Treatment of mice with BPV for 21 days did not induce protective antibodies. Serum (0.5 ml) from the BPV-treated

TABLE 6. Effect of heat on lymphocytosis after BPV treatment of C3H/HeN (+/nu) mice

Treatment	Peripheral blood leukocytes (cells/mm <sup>3</sup> );		
	Mean	SD	
Diluent	6,380	260	
BPV	17,600	3,800	
Heated BPV*	7,600	820	

TABLE 7. Effect of BPV treatment and MAdlpt4 infection on soleen weight

Treatment		Avg spleen w		
Day 6	Day 7	on day 10 (g)		
Diluent	Medium	0.090		
Diluent	$1.0 \times 10^{8} \text{ PFU}$	0.130		
BPV	Medium	0.352		
BPV	1.0 × 108 PFU	0.338		

<sup>&</sup>quot;Groups of three C3H/HeN (+/nu) mice were injected i.p. with vaccine diluent or 250 µg (dry weight) of BPV. Seven days later, the mice were injected i.p. with cell culture medium or virus stock. After 3 days the mice were sacrificed by cervical dis' cation, and the spleens were removed, blotted to remove excess fluid, and weighed.

C3H/HeN (MTV<sup>-</sup>) mice was injected i.p. into mice of the same strain and challenged with a high-dose virus inoculum 24 h later. Assuming a plasma volume of 1.1 ml (6), then potentially protective antibodies would have been diluted approximately threefold. A group of 10 mice treated in this manner succumbed to high-dose infection within 7 days.

#### DISCUSSION

Mouse adenovirus can be added to the list of virus infections that are modulated by treatment of the test animal with B. pertussis or materials derived from the microorganism. Development of the resistant state was not dependent on the strain of the microorganism. Although the B. pertussis strain from Connaught Laboratories, Inc., and strain 18323 (12) have a common lineage, strain Tohama I was derived from a completely different source (10). Development of the resistant state also was independent of the strain of mouse used.

The kinetics of development and decay of the resistant state indicated that a relatively long-term modification of the immunological mechanisms occurred. The modification probably did not involve thymus-derived lymphocytes in its mechanism of development, since congenitally athymic mice responded to BPV treatment with resistance. However, thymus involvement in the BPV-induced resistance in the thymus-bearing animal cannot be ruled out due to possible compensatory immune functions operating in congenitally athymic mice, such as increased numbers of natural killer cells. Thymus-derived cytolytic lymphocytes are necessary for final clearance of certain virus infections (11); consequently, the mechanism of BPV-induced resistance in thy-

TABLE 8. Effect of BPV treatment and MAd1pt4 infection on peritoneal leukocytes<sup>a</sup>

Treatment		Leukocytes in Peritoneal Lavage (cells × 10 <sup>-6</sup> per ml)			
		Day 7		Day 10	
Day 0	Day 7	Mean	SD	Mean	SD
Diluent		0.9	0.1	1.0	0.2
BPV		5.2	0.8	5.5	0.5
Diluent	$1.0 \times 10^8 \text{ PFU}$			1.1	0.2
BPV	$1.0 \times 10^8 \text{ PFU}$			10.0	1.0

<sup>&</sup>quot;Groups of six C3H/HeN (+/nu) mice were treated by i.p. inoculation of vaccine diluent or 250 µg (dry weight) of BPV. Seven days later three mice from each group were sacrificed by cervical dislocation, and 4.0 ml of Dulbecco modified minimal Eagle medium was injected into the peritoneum. The peritoneum was massaged, 3.5 ml of lavage was withdrawn, and the cells were counted. The remaining three mice in each group were inoculated with virus and sacrificed for lavage 3 days later.

Mice were injected i.p. with vaccine diluent or 250 µg (dry weight) of BPV (Connaught Laboratories) 4 days before bleeding.

<sup>&</sup>lt;sup>6</sup> BPV (Connaught Laboratories) was incubated at 80°C for 30 min before i.p. injection.




FIG. 1. Electron micrograph of ultrathin sections of peritoneal lavage cells f. ωm C3H/HeN (+/nu) mice. Ber. 1.0 μm. (A) Representative cell obtained after treatment with vaccine diluent (7 days) followed by MAd1pt4 infection (3 days). The inset shows an increased magnification of a phagolysosome containing virus particles. (B) Representative cell obtained after BPV treatment (7 days) followed by MAd1pt4 infection (3 days).

mus-bearing mice is probably an expression of retarded virus growth until the proper T-lymphocyte clones can develop. This conclusion is supported by the similarity of disease patterns in BPV-treated and low dose-infected athymic mice.

The immune response of mice appears to be overwhelmed by high-dose MAdlpt4 infection; death occurs before a systemic response in the form of splenomegaly, leukocytosis, and increase leukocytes in the peritoneum can develop. The treatment of mice with BPV could provide the mouse with a systemic response at the time of virus inoculation; however, one must consider that clinical signs of systemic response might not be involved in the resistant state. We have observed that acellular fractions of B. pertussis have decreased ability to induce splenomegaly and leukocytosis, yet retain resistance-inducing activity (R. S.

591

Stinson, J. D. Lee, L. Williamson, and A. Winters, Abstr. 19th Natl. Meet. Reticuloendothel. Soc. 1982, abstr. no. 56, p. 70). The mechanism of BPV-induced resistance markedly decreased virus particles from the inoculum or subsequent multiplication in peritoneal lavage cells obtained 3 days after infection (or both).

Study of the molecules or complex of molecules in B. pertussis that are responsible for induction of the virus-resistant state, and investigation of their mechanism of immunomodulation might lead to new methods for prevention and treatment of virus infections.

#### **ACKNOWLEDGMENTS**

This work was initiated at the Department of Medical Microbiology and Immunology, University of South Florida, Tampa. Support was provided by University of Alabama Research Committee projects no. 1116 and 1143, Public Health Service Biomedical research support grants NIH 5 S07 RR05749-05 and PHS 2 S07 RR07151-06 from the National Institutes of Health, Public Health Service Grant AI 15108-01 from the National Institutes of Allergy and Infecticus Disease, and Office of Naval Research contract N00014-83-K-0597.

#### LITERATURE CITED

Ayme, G., M. Caroff, R. Chaby, N. Haeffner-Cavaillon, A. LeDur, M. Morean, M. Muset, M.-C. Mynard, M. Roumiantzeff, D. Schulz, and L. Szaba. 1980. Biological activities of iragments derived from Bordetella pertussis endotoxin: isolation of a nontoxic, Shwartzman-negative lipid A possessing high adjuvant properties. Infect. Immun. 27:739-745.

Balachandran, N., S. Bacchetti, and W. E. Rawis. 1982. Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex

virus type 2. Infect. Immun. 37:1132-1137.

Chaby, R., G. Ayme, M. Caroff, R. Donikian, N. Haeffner-Cavaillon, A. Le Dur, M. Moresu, M.-C. Mynard, M. Roumi-antaeff, and L. Sanbo. 1979. Structural features and separation of some of the biological activities of the Bordetella pertussis endotoxin by chemical fractionation, p. 185-190. In C. R. Manclark and J. C. Hill (ed.), International symposium on pertussis. Department of Health, Education, and Welfare publication no. (NIH)79-1830. U.S. Government Printing Office, Washington, D.C.

 Flsh, F., J. L. Cowell, and C. R. Manclark. 1984. Proliferative response of immune mouse T-lymphocytes to the lymphocytosispromoting factor of *Bordetella pertussis*. Infect. Immun. 44:1-6.

- Fishel, C. W., D. G. Halkias, T. W. Klein, and A. Szentivanyi. 1976. Characterization of cells present in peritoneal fluids of mice injected intraperitoneally with *Bordetella pertussis*. Infect. Immun. 13:263-272.
- Friedman, J. J. 195>. Circulating and tissue hematocrits of normal unanesthetized mice. Am. J. Physiol. 196:420-422.
- Hewlett, E. L., C. O. Roberts, J. Wolff, and C. R. Manclark. 1983. Biphasic effect of pertussis vaccine on serum insulin in mice. Infect. Immun. 41:137-144.
- Ho, M.-K., A. S. Kong, and S. I. Morse. 1980. The in vitro effects of Bordetetia pertussis lymphocytosis-promoting factor on murine lymphocytes. V. Modulation of T cell proliferation by helper and suppressor lymphocytes. J. Immunol. 124:

362\_369

- Jerne, N. K., C. Henry, A. A. Nordin, H. Fuji, A. M. C. Koros, and L. Lefkevite. 1976. Antibody synthesis in vitro. Methods Immunol. Immunochem. 5:303-374.
- Kasuga, T., Y. Nakase, K. Ukishima, and K. Takatsu. 1954.
   Studies on Haemophilus pertussis. V. Relation between the phase of bacilli and the progress of the whooping-cough. Kitasato Arch. Exp. Med. 27:57-62.
- Kees, U., and R. V. Blanden. 1976. A single genetic element in H-2K affects mouse T-cell antiviral function in poxvirus infection. J. Exp. Med. 143:450-455.
- Kendrick, P. L., G. Eldering, M. K. Dixon, and J. Misner. 1947.
   Mouse protection tests in the study of pertussis vaccine: a comparative series using the intracerebral route for challenge.
   Am. J. Public Health 37:803-810.
- Kirchner, H., M. T. Scott, H. M. Hirt, and K. Munk. 1978.
   Protection of mice against viral infection by Corynebacterium parvum and Bordetella pertussis. J. Gen. Virol. 41:97-104.
- Klein, T., W. Benjamin, A. Winters, and H. Friedman. 1981. Pertussis induced immunomodulation, p. 275-292. In H. Friedman, T. W. Klein, and A. Szentivanyi (ed.), Immunomodulation by bacteria and their products. Plenum Publishing Corp., New York.
- LeFrancois, L. 1984. Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: distinct mechanisms of action in vivo. J. Virol. 51:208-214.
- Mathews, J. H., and J. T. Roehrig. 1982. Determination of the protective epitopes on the glycoproteins of Venezuelan equine encephalomyelitis virus by passive transfer of monoclonal antibodies. J. Immunol. 129:2763-2767.
- 17. Marse, S. I. 1976. Biologically active components and properties of *Bordetella pertussis*. Adv. Appl. Microbiol. 20:2-25.
- Munes, J. J., H. Arai, R. K. Bergman, and P. L. Sadowski. 1981.
   Biological activities of crystalline pertussigen from *Bordetella pertussis*. Infect. Immun. 33:820-826.
- Munes, J. J., and R. K. Bergman. 1977. Bordetella pertussis, immunological and other biological activities, vol. 4. Marcel Dekker, Inc., New York.
- Munes, J. J., and R. K. Bergman. 1979. Biological activities of Bordetella pertussis, p. 143-150. In C. R. Manclark and J. C. Hill (ed.), International symposium on pertussis. Department of Health, Education, and Welfare publication no. (NIH)79-1830. U.S. Government Printing Office, Washington, D.C.
- Parfentjev, I. A. 1955. Bacterial allergy increases susceptibility to influenza virus in mice. Proc. Soc. Exp. Biol. Med. 99-172-375
- Sets, Y., J. L. Cowell, H. Sato, D. G. Burstyn, C. R. Manclark.
   1983. Separation and purification of the hemagglutinins from Bordetella pertussis. Infect. Immun. 41:313-320.
- Sugimoto, M., Y. Nakanishi, M. Otokawa, N. Uchida, T. Yasuda, H. Sato, and Y. Sato. 1983. Effect of Bordetella pertussis leukocytosis(lymphocytosis)-promoting factor (LPF) on the physical lymphoepithelial-cell association studied with the use of an in vitro model of mouse thymus. J. Immunol. 136:2767-2774.
- Winters, A. L., and H. K. Brown. 1980. Duodenal lesions associated with adenovirus infection in athymic "nude" mice. Proc. Soc. Exp. Biol. Med. 164:280-286.
- Winters, A. L., H. K. Brown, and J. K. Carlson. 1981. Interstitial pneumonia induced by a plaque-type variant of mouse adenovirus. Proc. Soc. Exp. Biol. Med. 167:359-364.

#### DISTRIBUTION LIST

### Lamunological Defense Program

# Annual, Final and Technical Reports (one copy each except as noted)

Dr. John D. Clements
Department of Microbiology
and Immunology
Tulane University
1430 Tulane Avenue
New Orleans, LA 70112

Francis A. Ennis, M.D.
Department of Medicine
University of Massachusettes
Medical School
55 Lake Avenue
Worcester, MA 01605

Dr. Edward A. Havell Trudeau Institute P.O. Box 59 Saranac Lake, NY 12983

Dr. Arthur G. Johnson
Department of Medical
Microbiology and Immunology
University of Minnesota
School of Medicine
2205 East 5th Street
Duluth, MN 55812

Dr. Matthew J. Kluger
Department of Physiology
University of Michigan Med. School
7620 Medical Science II Building
Ann Arbor, MI 48109

Dr. Roger M. Loria
Department of Microbiology
and Immunology
Virginia Commonwealth University
Box 678, MCV Station
Richmond, VA 23298-0001

Dr. Ernest D. Marquez Bioassay Systems Corporation 225 Wildwood Avenue Woburn, MA 01801 Dr. Robert I. Mishell
Department of Microbiology
and Immunology
University of California, Berkeley
Berkeley, CA 94720

James J. Mond, M.D.
Department of Medicine
Uniformed Services University
of the Health Sciences
4301 Jones Bridge Road
Bethesda, MD 20814

Dr. Page S. Morahan
Department of Microbiology
Medical College of Pennsylvania
3300 Henry Avenue
Philadelphia, PA 19129

David A. Stevens, M.D.
Department of Medicine
Santa Clara Valley Medical Center
Stanford University
751 S. Bascom Avenue
San Jose, CA 95128

Dr. Barnet M. Sultzer
Department of Microbiology
and Immunology
Downstate Medical Center
450 Clarkson Avenue

G. Jeanette Thorbecke, M.D. Department of Pathology
New York University
School of Medicine
550 First Avenue
New York, NY 10016

Dr. Alvin L. Winters
Department of Microbiology
University of Alabama
University, AL 35486

## Annual, Final and Technical Reports (one copy each except as noted)

Br. Jeannine A. Majde, Code 441CB Scientific Officer, Immunology Program Office of Maval Research 800 M. Quincy Street Arlington, VA 22217

Administrator (2 copies) (Enclose DTIC Form 50) Defense Technical Information Center Building 5, Cameron Station Alexandria, VA 22314

### Annual and Final Reports Only (one copy each)

Commanding Officer Waval Medical Command Washington, DC 20372

Commanding Officer
Naval Medical Research & Development Command
National Naval Medical Center
Bethesda, MD 20814

Director, Infectious Diseases Program Center Naval Medical Research Institute National Naval Medical Center Bethesda, MD 20814

Commander Chemical and Biological Sciences Division Army Research Office, P.O. Box 12211 Research Triangle Park, NC 27709

Commander
U.S. Army Research and Development Command
Attn: SGRD-PLA
Fort Detrick
Frederick, MD 21701

Commander
USAMKIID
Fort Detrick
Frederick, MD 21701

Directorate of Life Sciences Air. Force Office of Scientific Research Bolling Air Force Base Washington, DC 20332

Administrative Contracting Officer
ONR Resident Representative
(address varies - obtain from Business Office)

### Final and Technical Reports Only

Director, Waval Research Laboratory (6 copies) Attn: Technical Information Division, Code 2627 Washington, DC 20375